An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients in Italy

被引：2
|
作者：
Rudelli, G
Annemans, L
Spiesser, J
Novelli, M
Walker, A
Gabriel, S
机构：
[1] Sanofi Synthelabo, Milan, Italy
[2] HEDM, Meise, Belgium
[3] Sanofi Synthelabo Rech, Bagneux, France
[4] Bristol Myers Squibb, Rome, Italy
[5] Bristol Myers Squibb, Rueil Malmaison, France
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65788-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：686 / 687
页数：2
相关论文
共 50 条
  • [31] Clopidogrel Versus Aspirin in Patients with Recent Ischemic Stroke and Established Peripheral Artery Disease: An Economic Evaluation in a Chinese Setting
    Li, Te
    Liu, Maobai
    Ben, He
    Xu, Zhenxing
    Zhong, Han
    Wu, Bin
    CLINICAL DRUG INVESTIGATION, 2015, 35 (06) : 365 - 374
  • [32] Clopidogrel Versus Aspirin in Patients with Recent Ischemic Stroke and Established Peripheral Artery Disease: An Economic Evaluation in a Chinese Setting
    Te Li
    Maobai Liu
    He Ben
    Zhenxing Xu
    Han Zhong
    Bin Wu
    Clinical Drug Investigation, 2015, 35 : 365 - 374
  • [33] Cost-effectiveness of clopidogrel versus aspirin in the prevention of ischemic events in stroke and tia patients: A four-European country analysis
    Palmer, AJ
    Roze, S
    Hankey, G
    Hakimi, Z
    Spiesser, J
    Carita, P
    Gabriel, S
    VALUE IN HEALTH, 2005, 8 (03) : 334 - 334
  • [34] Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial
    Morrow, David A.
    Scirica, Benjamin M.
    Fox, Keith A. A.
    Berman, Gail
    Strony, John
    Veltri, Enrico
    Bonaca, Marc P.
    Fish, Polly
    McCabe, Carolyn H.
    Braunwald, Eugene
    AMERICAN HEART JOURNAL, 2009, 158 (03) : 335 - 341
  • [35] Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke A Secondary Analysis of the POINT Randomized Clinical Trial
    Tillman, Holly
    Johnston, S. Claiborne
    Farrant, Mary
    Barsan, William
    Elm, Jordan J.
    Kim, Anthony S.
    Lindblad, Anne S.
    Palesch, Yuko Y.
    Easton, J. Donald
    JAMA NEUROLOGY, 2019, 76 (07) : 774 - 782
  • [36] HEALTH ECONOMIC EVALUATION OF CATHETER BASED PFO CLOSURE FOR SECONDARY PREVENTION OF ISCHEMIC IN YOUNG PATIENTS
    Hagen, G.
    VALUE IN HEALTH, 2020, 23 : S266 - S266
  • [37] PREVENTION OF ISCHEMIC CEREBRAL EVENTS BY DETECTION OF ATRIAL FIBRILLATION IN HIGH RISK PATIENTS.
    Hartog, M.
    Hartog, L.
    Hartog, J.
    Groothuis, J.
    Wind, A.
    Aertsen, M.
    ATHEROSCLEROSIS, 2019, 287 : E277 - E277
  • [38] Roundtable discussion: Clinical safety and efficacy of clopidogrel-implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease
    Ferguson, JJ
    Gonzalez, ER
    Kannel, WB
    Olin, JW
    Raps, EC
    CLINICAL THERAPEUTICS, 1998, 20 : B42 - B53
  • [39] Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
    Fragoulakis, Vassilis
    Kourlaba, Georgia
    Maniadakis, Nikolaos
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 135 - 143
  • [40] Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing serious vascular events in high vascular risk patients.
    Hankey, G
    Sudlow, C
    Dunbabin, O
    STROKE, 2000, 31 (11) : 2868 - 2868
12345